Thorsten Simon

Summary

Affiliation: University of Cologne
Country: Germany

Publications

  1. ncbi request reprint Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis
    Thorsten Simon
    Department of Pediatric Oncology and Hematology, Children s Hospital, University of Cologne, Cologne, Germany
    J Clin Oncol 31:752-8. 2013
  2. doi request reprint Short- and long-term outcome of patients with symptoms of spinal cord compression by neuroblastoma
    Thorsten Simon
    Department of Pediatric Oncology and Hematology, Children s Hospital, University of Cologne, Cologne, Germany
    Dev Med Child Neurol 54:347-52. 2012
  3. ncbi request reprint Slow progression of a small Wilms' tumor
    T Simon
    Pädiatrische Hämatologie Onkologie, Universitätsklinikum Köln, Koln, Germany
    Klin Padiatr 222:190-1. 2010
  4. ncbi request reprint Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease
    Thorsten Simon
    Children s Hospital, University of Cologne, Germany
    Strahlenther Onkol 182:389-94. 2006
  5. ncbi request reprint Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial
    Thorsten Simon
    Department of Pediatric Oncology and Hematology, Children s Hospital, University of Cologne, Cologne, Germany
    J Pediatr Hematol Oncol 29:101-6. 2007
  6. ncbi request reprint Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial
    Thorsten Simon
    Children s Hospital, Department of Pediatric Oncology and Hematology, University of Cologne, Kerpener Strasse 62, 50924 Cologne, Germany
    J Cancer Res Clin Oncol 133:653-61. 2007
  7. doi request reprint Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials
    Thorsten Simon
    Department of Pediatric Oncology and Hematology, Children s Hospital, University of Cologne, Cologne, Germany
    Pediatr Blood Cancer 56:578-83. 2011
  8. ncbi request reprint Risk estimation in localized unresectable single copy MYCN neuroblastoma by the status of chromosomes 1p and 11q
    Thorsten Simon
    Department of Pediatric Oncology and Hematology, Children s Hospital, University of Cologne, Kerpener Str 62, D 50924 Koln, Germany
    Cancer Lett 237:215-22. 2006
  9. ncbi request reprint Review of image defined risk factors in localized neuroblastoma patients: Results of the GPOH NB97 trial
    Thorsten Simon
    Department of Pediatric Oncology and Hematology, Children s Hospital, University of Cologne, Germany
    Pediatr Blood Cancer 50:965-9. 2008
  10. ncbi request reprint Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy
    T Simon
    Children s Hospital, University of Cologne, Germany
    Klin Padiatr 217:147-52. 2005

Detail Information

Publications40

  1. ncbi request reprint Role of surgery in the treatment of patients with stage 4 neuroblastoma age 18 months or older at diagnosis
    Thorsten Simon
    Department of Pediatric Oncology and Hematology, Children s Hospital, University of Cologne, Cologne, Germany
    J Clin Oncol 31:752-8. 2013
    ..Although intensive multimodal treatment has improved the prognosis of patients with metastatic neuroblastoma, the impact of primary tumor resection on outcome is a matter of medical debate...
  2. doi request reprint Short- and long-term outcome of patients with symptoms of spinal cord compression by neuroblastoma
    Thorsten Simon
    Department of Pediatric Oncology and Hematology, Children s Hospital, University of Cologne, Cologne, Germany
    Dev Med Child Neurol 54:347-52. 2012
    ..Prospective trials on neuroblastoma-induced myelopathy are lacking. Therefore, we retrospectively analysed patients in four national neuroblastoma trials...
  3. ncbi request reprint Slow progression of a small Wilms' tumor
    T Simon
    Pädiatrische Hämatologie Onkologie, Universitätsklinikum Köln, Koln, Germany
    Klin Padiatr 222:190-1. 2010
    ..The case demonstrates that even small renal lesions require diagnostic work-up and adequate treatment...
  4. ncbi request reprint Intensified external-beam radiation therapy improves the outcome of stage 4 neuroblastoma in children > 1 year with residual local disease
    Thorsten Simon
    Children s Hospital, University of Cologne, Germany
    Strahlenther Onkol 182:389-94. 2006
    ..The impact of external-beam radiation therapy (EBRT) on event-free (EFS) and overall survival (OS) of stage 4 neuroblastoma patients of the NB97 trial was analyzed...
  5. ncbi request reprint Topotecan and etoposide in the treatment of relapsed high-risk neuroblastoma: results of a phase 2 trial
    Thorsten Simon
    Department of Pediatric Oncology and Hematology, Children s Hospital, University of Cologne, Cologne, Germany
    J Pediatr Hematol Oncol 29:101-6. 2007
    ..We conclude that the combination of TE is effective and tolerable in the treatment of relapsed high-risk neuroblastoma...
  6. ncbi request reprint Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial
    Thorsten Simon
    Children s Hospital, Department of Pediatric Oncology and Hematology, University of Cologne, Kerpener Strasse 62, 50924 Cologne, Germany
    J Cancer Res Clin Oncol 133:653-61. 2007
    ..Relapsed high-risk neuroblastoma patients still have a poor prognosis. This phase-II trial assessed a new topotecan containing chemotherapy approach in patients with active disease...
  7. doi request reprint Treatment and outcomes of patients with relapsed, high-risk neuroblastoma: results of German trials
    Thorsten Simon
    Department of Pediatric Oncology and Hematology, Children s Hospital, University of Cologne, Cologne, Germany
    Pediatr Blood Cancer 56:578-83. 2011
    ..However, many patients experience relapse after successful initial treatment. We retrospectively analyzed the long-term outcome of relapsed patients of three consecutive national neuroblastoma trials...
  8. ncbi request reprint Risk estimation in localized unresectable single copy MYCN neuroblastoma by the status of chromosomes 1p and 11q
    Thorsten Simon
    Department of Pediatric Oncology and Hematology, Children s Hospital, University of Cologne, Kerpener Str 62, D 50924 Koln, Germany
    Cancer Lett 237:215-22. 2006
    ..Aberrations of chromosome 11q in 14/91 patients were correlated with a higher event and death rate. Multivariate analysis identified 1p aberrations as important for event free survival and 11q aberrations for overall survival...
  9. ncbi request reprint Review of image defined risk factors in localized neuroblastoma patients: Results of the GPOH NB97 trial
    Thorsten Simon
    Department of Pediatric Oncology and Hematology, Children s Hospital, University of Cologne, Germany
    Pediatr Blood Cancer 50:965-9. 2008
    ..Localized disease can be classified as L1 without and as L2 with image defined risk factors (IDRF published in JCO 2005; 23:8483-8489). Our aim was to evaluate IDRF for the prediction of resectability, complications, and outcome...
  10. ncbi request reprint Infants with stage 4 neuroblastoma: the impact of the chimeric anti-GD2-antibody ch14.18 consolidation therapy
    T Simon
    Children s Hospital, University of Cologne, Germany
    Klin Padiatr 217:147-52. 2005
    ..Antibody treatment is considered tolerable and potentially effective in the therapy of neuroblastoma. We have analyzed the clinical data of infants < 1 year with stage 4 neuroblastoma with regard to the consolidation treatment...
  11. ncbi request reprint [Neuroblastoma]
    T Simon
    Pädiatrische Onkologie und Hämatologie, Klinik und Poliklinik für Kinder und Jugendmedizin, Universitat Koln
    Urologe A 44:543-54; 555. 2005
    ..Therefore, the treatment of neuroblastoma must be risk adapted. The 5 year overall survival rates in the German NB97 trial were 96+/-1% in the observation group, 89+/-3% in the median risk group, and 50+/-3% in the high risk group...
  12. ncbi request reprint New definition of low-risk neuroblastoma using stage, age, and 1p and MYCN status
    Thorsten Simon
    Children s Hospital, Department of Pediatric Oncology and Hematology, University of Cologne, Joseph Stelzmann Strasse 9, 50924 Köln, Germany
    J Pediatr Hematol Oncol 26:791-6. 2004
    ..7 +/- 6.5%, P < 0.001; 3-year OS 83.4 +/- 4.5%; P < 0.001). The authors conclude that postoperative chemotherapy is required only in a small group of patients with localized and stage 4S disease without MYCN amplification...
  13. ncbi request reprint Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma
    Thorsten Simon
    Children s Hospital, Department of Pediatric Oncology and Hematology, University of Cologne, Germany
    J Clin Oncol 22:3549-57. 2004
    ..We have analyzed stage 4 neuroblastoma patients older than 1 year who underwent consolidation treatment with the chimeric monoclonal anti-GD2-antibody ch14.18...
  14. ncbi request reprint Multiple malignant diseases in a patient with Rothmund-Thomson syndrome with RECQL4 mutations: Case report and literature review
    T Simon
    Department of Pediatric Oncology and Hematology, Children s Hospital, University of Cologne, Cologne, Germany
    Am J Med Genet A 152:1575-9. 2010
    ..The most remarkable clinical features are young age, spontaneous remission of diffuse large cell lymphoma, and severe CNS and skin toxicity of cytotoxic treatment...
  15. pmc Long term outcome of high-risk neuroblastoma patients after immunotherapy with antibody ch14.18 or oral metronomic chemotherapy
    Thorsten Simon
    Children s Hospital, University of Cologne, Cologne, Germany
    BMC Cancer 11:21. 2011
    ..We applied metronomic chemotherapy in the prospective NB90 trial and monoclonal anti-GD2-antibody (MAB) ch14.18 in the NB97 trial. Here, we present the long term outcome data of the patient cohort...
  16. ncbi request reprint Myeloablative megatherapy with autologous stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial
    Frank Berthold
    Children s Hospital and Centre for Molecular Medicine, University of Cologne, Cologne, Germany
    Lancet Oncol 6:649-58. 2005
    ..We aimed to assess whether megatherapy with autologous stem-cell transplantation could increase event-free survival and overall survival compared with maintenance chemotherapy...
  17. doi request reprint Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97
    Barbara Hero
    Children s Hospital, Department of Pediatric Oncology and Hematology, University of Cologne, Kerpener Str 62, 50924 Cologne, Germany
    J Clin Oncol 26:1504-10. 2008
    ....
  18. ncbi request reprint Loss in chromosome 11q identifies tumors with increased risk for metastatic relapses in localized and 4S neuroblastoma
    Ruediger Spitz
    Authors Affiliations Department of Pediatric Oncology, University Children s Hospital, Koln, Germany
    Clin Cancer Res 12:3368-73. 2006
    ..To improve risk prediction in neuroblastoma and to specify the type of a possible relapse, alterations in the long arm of chromosome 11 were analyzed...
  19. ncbi request reprint Oligonucleotide array-based comparative genomic hybridization (aCGH) of 90 neuroblastomas reveals aberration patterns closely associated with relapse pattern and outcome
    Ruediger Spitz
    Children s Hospital, Department of Paediatric Oncology and Haematology, University of Cologne, Koln, Germany
    Genes Chromosomes Cancer 45:1130-42. 2006
    ..One single feature in 21q21.1 (BU678720, without known function yet) attracted particular attention since five patients showed a homozygous loss of this sequence...
  20. doi request reprint The prognostic impact of functional imaging with (123)I-mIBG in patients with stage 4 neuroblastoma >1 year of age on a high-risk treatment protocol: results of the German Neuroblastoma Trial NB97
    Matthias Schmidt
    Department of Nuclear Medicine, University of Cologne, Kerpener Street, 62, 50937 Köln Cologne, Germany
    Eur J Cancer 44:1552-8. 2008
    ..The presence of any (123)I-mIBG positive tumour tissue was correlated with event-free survival (EFS) and overall survival (OS)...
  21. ncbi request reprint Iodine-123 metaiodobenzylguanidine scintigraphy scoring allows prediction of outcome in patients with stage 4 neuroblastoma: results of the Cologne interscore comparison study
    Boris Decarolis
    University Hospital of Cologne, Kerpener Str 62, 50937 Cologne, Germany
    J Clin Oncol 31:944-51. 2013
    ..We present the results of the comparison between the SIOPEN [International Society of Pediatric Oncology Europe Neuroblastoma Group] score and the modified Curie score...
  22. ncbi request reprint Stereotactic iodine-125 brachytherapy for treatment of inoperable focal brainstem gliomas of WHO grades I and II: feasibility and long-term outcome
    Maximilian I Ruge
    Department of Stereotactic and Functional Neurosurgery, University Hospital of Cologne, Kerpener Straße 62 Main Clinic Building 11th Floor, 50937, Cologne, Germany
    J Neurooncol 109:273-83. 2012
    ..6 ± 7.0 % (10 years). SBT is a comparatively safe, minimally invasive, and highly effective local treatment option for patients with inoperable F-BSG WHO grades I and II; it merits further evaluation in prospective randomized trials...
  23. pmc Co-regulated expression of HAND2 and DEIN by a bidirectional promoter with asymmetrical activity in neuroblastoma
    Harald Voth
    Department of Pediatric Oncology and Hematology and Center of Molecular Medicine Cologne CMMC, University Children s Hospital, Cologne, Germany
    BMC Mol Biol 10:28. 2009
    ..The similar expression profile of both genes suggests a common transcriptional regulation mediated by a bidirectional promoter...
  24. ncbi request reprint Favorable outcome of triploid neuroblastomas: a contribution to the special oncogenesis of neuroblastoma
    Ruediger Spitz
    Department of Pediatric Oncology, University Children s Hospital, Joseph Stelzmann Str 9, 50924 Cologne, Germany
    Cancer Genet Cytogenet 167:51-6. 2006
    ..The sharp decline of trisomic tumors after the age of 18 months supports the idea of different genetic tumor entities...
  25. ncbi request reprint Focal nodular hyperplasia of the liver in longterm survivors of neuroblastoma: how much diagnostic imaging is necessary?
    Gabriele Benz-Bohm
    Division of Pediatric Radiology, A Gossmann formerly, Department of Radiology, University of Cologne, Kerpenerstr 62, 50924 Köln, Germany
    Eur J Radiol 74:e1-5. 2010
    ..The aetiology is unclear, the pathogenesis remains controversial. Focal nodular hyperplasia of the liver is suspected to be a sequela of tumor therapy...
  26. doi request reprint Heterogeneity of the MYCN oncogene in neuroblastoma
    Jessica Theissen
    Department of Pediatric Oncology and Hematology, Children s Hospital, University of Cologne, Cologne, Germany
    Clin Cancer Res 15:2085-90. 2009
    ..MYCN amplification is an important therapy-stratifying marker in neuroblastoma. Fluorescence in situ hybridization with signal detection on the single-cell level allows a critical judgement of MYCN intratumoral heterogeneity...
  27. ncbi request reprint Chromosome 17/17q gain and unaltered profiles in high resolution array-CGH are prognostically informative in neuroblastoma
    Jessica Theissen
    Department of Pediatric Oncology and Hematology, Children s Hospital, University of Cologne, Cologne, Germany
    Genes Chromosomes Cancer 53:639-49. 2014
    ..The group of tumors with partial gain was similar to the group without gain with respect to stage distribution, outcome, and gene expression profile...
  28. ncbi request reprint Dosimetry for 131I-MIBG therapies in metastatic neuroblastoma, phaeochromocytoma and paraganglioma
    Ferdinand Sudbrock
    Department of Nuclear Medicine, University of Cologne, Cologne, Germany
    Eur J Nucl Med Mol Imaging 37:1279-90. 2010
    ..This work presents our procedures, the dosimetric data and experiences with TRT using (131)I-MIBG...
  29. doi request reprint Prognostic impact of gene expression-based classification for neuroblastoma
    Andre Oberthuer
    University of Cologne, Cologne, Germany
    J Clin Oncol 28:3506-15. 2010
    ..To evaluate the impact of a predefined gene expression-based classifier for clinical risk estimation and cytotoxic treatment decision making in neuroblastoma patients...
  30. doi request reprint Identification of DEIN, a novel gene with high expression levels in stage IVS neuroblastoma
    Harald Voth
    Department of Pediatric Oncology and Hematology, University Children s Hospital of Cologne, Kerpener Strasse 62, 50924 Cologne, Germany
    Mol Cancer Res 5:1276-84. 2007
    ..001). The characteristic expression pattern of DEIN suggests a specific role of this gene in the unique biology of stage IVS tumors and may help to molecularly define this special subtype of neuroblastoma...
  31. doi request reprint Diagnostic value and safety of stereotactic biopsy for brainstem tumors: a systematic review and meta-analysis of 1480 cases
    Philipp Kickingereder
    Department of Stereotactic and Functional Neurosurgery, University Hospital of Cologne, Cologne, Germany
    Neurosurgery 72:873-81; discussion 882; quiz 882. 2013
    ..Hence, a molecular stereotactic biopsy that combines histopathological diagnosis with molecular-genetic analysis will become increasingly important for patients with BSTs...
  32. ncbi request reprint Is there a benefit of 131 I-MIBG therapy in the treatment of children with stage 4 neuroblastoma? A retrospective evaluation of The German Neuroblastoma Trial NB97 and implications for The German Neuroblastoma Trial NB2004
    M Schmidt
    Department of Nuclear Medicine, University of Cologne, Kerpener Strasse 62, 50937 Koln, Germany
    Nuklearmedizin 45:145-51; quiz N39-40. 2006
    ..131)I-meta-iodobenzylguanidine ((131)I-MIBG) therapy has been used in neuroblastoma treatment for many years but its value in high intensive first line treatment protocols is not exactly known...
  33. doi request reprint Stereotactic brachytherapy with iodine-125 seeds for the treatment of inoperable low-grade gliomas in children: long-term outcome
    Maximilian I Ruge
    University of Cologne, Cologne, Germany
    J Clin Oncol 29:4151-9. 2011
    ..This single-center study provides a summary of the long-term outcome after SBT in one of the largest reported patient series...
  34. ncbi request reprint Long-term results and risk profiles of patients in five consecutive trials (1979-1997) with stage 4 neuroblastoma over 1 year of age
    F Berthold
    Department of Pediatric Oncology and Hematology, Children s Hospital, University of Cologne, Joseph Stelzmann Str 9, 50924 Cologne, Germany
    Cancer Lett 197:11-7. 2003
    ..04 (NB97). The overall survival rates improved similarly from 0.04 (NB79) to 0.44 (NB97). In conclusion, the improved survival was associated with better treatment and not caused by lower risk profiles in stage 4 neuroblastoma patients...
  35. ncbi request reprint The incidence of hearing impairment after successful treatment of neuroblastoma
    T Simon
    Children s Hospital, Koln, Germany
    Klin Padiatr 214:149-52. 2002
    ..Platinum compound based chemotherapy has contributed to improved survival rates in neuroblastoma patients. We studied the association of hearing loss with the use of platinum based drugs...
  36. ncbi request reprint Tumour markers are poor predictors for relapse or progression in neuroblastoma
    T Simon
    Children s Hospital, University of Cologne, 50924 Cologne, Germany
    Eur J Cancer 39:1899-903. 2003
    ..Relapse or progression in neuroblastoma cannot be detected reliably by monitoring tumour markers alone. Therefore, follow-up of neuroblastoma patients must include clinical assessment and imaging studies...
  37. ncbi request reprint Metastatic neuroblastoma in infancy: what does the pattern of metastases contribute to prognosis?
    B Hero
    Children s Hospital, University of Cologne, Koln, Germany
    Med Pediatr Oncol 35:683-7. 2000
    ..The purpose was to investigate the influence of metastatic pattern and primary extension over midline on prognosis of infants with metastatic neuroblastoma...
  38. ncbi request reprint The role of age in neuroblastoma risk stratification: the German, Italian, and children's oncology group perspectives
    Wendy B London
    University of Florida and Children s Oncology Group Department of Statistics, 104 N Main St, 600, Gainesville, FL 32601, USA
    Cancer Lett 228:257-66. 2005
    ..However, Italian results in INSS stage 4 patients show that outcome in patients 12-17 months is not better than that of older patients. Further analyses are warrented...
  39. ncbi request reprint Epidural compression in neuroblastoma: Diagnostic and therapeutic aspects
    Bruno De Bernardi
    Department of Haematology Oncology, Giannina Gaslini Children s Hospital, Largo Gerolamo Gaslini, 5, 16148 Genova, Italy
    Cancer Lett 228:283-99. 2005
    ....
  40. ncbi request reprint Activation of Akt predicts poor outcome in neuroblastoma
    Daniela Opel
    University Children s Hospital, Ulm, Germany
    Cancer Res 67:735-45. 2007
    ....